Overview

Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia

Status:
Completed
Trial end date:
2020-09-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of MT-5199 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation